ARS Pharmaceuticals Inc (NASDAQ: SPRY) is 144.16% higher on its value in year-to-date trading and has touched a low of $4.64 and a high of $18.51 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SPRY stock was last observed hovering at around $13.55 in the last trading session, with the day’s loss setting it -0.17%.
Currently trading at $13.38, the stock is -10.62% and -9.36% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing -1.25% at the moment leaves the stock 22.43% off its SMA200. SPRY registered 184.68% gain for a year compared to 6-month gain of 52.05%. The firm has a 50-day simple moving average (SMA 50) of $14.7468 and a 200-day simple moving average (SMA200) of $10.89295.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -16.64% loss in the last 1 month and extending the period to 3 months gives it a 3.24%, and is -5.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.06% over the week and 7.44% over the month.
ARS Pharmaceuticals Inc (SPRY) has around 26 employees, a market worth around $1.30B and $2.57M in sales. Profit margin for the company is -1912.15%. Distance from 52-week low is 188.36% and -27.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.43%).
The EPS is expected to grow by 12.72% this year
212.0 institutions hold shares in ARS Pharmaceuticals Inc (SPRY), with institutional investors hold 88.64% of the company’s shares. The shares outstanding are 96.41M, and float is at 50.64M with Short Float at 24.88%. Institutions hold 68.11% of the Float.
The top institutional shareholder in the company is DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with over 11.08 million shares valued at $94.27 million. The investor’s holdings represent 11.4409 of the SPRY Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 10.86 million shares valued at $92.43 million to account for 11.2168 of the shares outstanding. The other top investors are ORBIMED ADVISORS LLC which holds 9.24 million shares representing 9.5436 and valued at over $78.64 million, while SR ONE CAPITAL MANAGEMENT, LP holds 4.1444 of the shares totaling 4.01 million with a market value of $34.15 million.
ARS Pharmaceuticals Inc (SPRY) Insider Activity
The most recent transaction is an insider sale by Lowenthal Richard E, the company’s PRESIDENT AND CEO. SEC filings show that Lowenthal Richard E sold 100,000 shares of the company’s common stock on Nov 19 ’24 at a price of $13.95 per share for a total of $1.39 million. Following the sale, the insider now owns 1.2 million shares.
ARS Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 19 ’24 that Tanimoto Sarina (CHIEF MEDICAL OFFICER) sold a total of 100,000 shares of the company’s common stock. The trade occurred on Nov 19 ’24 and was made at $13.95 per share for $1.39 million. Following the transaction, the insider now directly holds 1.2 million shares of the SPRY stock.
Still, SEC filings show that on Nov 15 ’24, Chakma Justin (Officer) Proposed Sale 236,380 shares at an average price of $17.30 for $4.09 million. The insider now directly holds shares of ARS Pharmaceuticals Inc (SPRY).
